Cognition Therapeutics annual revenue
2022
2023
2024
2025
Cognition Therapeutics Revenue Growth & History (CGTX)
Cognition Therapeutics reported $0 in revenue for fiscal 2025.
View full Cognition Therapeutics company overviewCognition Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | $0 | — |
| 2024 | 2024-12-31 | $0 | $0 | — |
| 2023 | 2023-12-31 | $0 | $0 | — |
| 2022 | 2022-12-31 | $0 | — | — |
Cognition Therapeutics quarterly revenue
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | — | — |
| Q4 2025 | 2025-12-31 | $0 | — | — |
| Q3 2025 | 2025-09-30 | $0 | — | — |
| Q2 2025 | 2025-06-30 | $0 | — | — |
Cognition Therapeutics revenue growth trends
Cognition Therapeutics's latest reported quarter, Q2 2026, generated $0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Cognition Therapeutics source filings ↗Community posts
Cognition aligns with FDA on pivotal Lewy body dementia trial
Cognition Therapeutics ($CGTX) said it reached agreement with the FDA on key elements of a planned pivotal Phase 3 study of zervimesine, also known as CT1812, in dementia with Lewy bodies. The proposed trial would compare a 100-milligram da ...
